Horseshoe crab anti-endotoxin factor analogue peptide molecule, synthetic method and use thereof

Abstract

The invention discloses an analog peptide molecule of antiendotoxin factor of Limulida to kill bacteria and treat endotoxin blood symptom, which applies computer molecular analog technique to design the following 6 groups of analog peptides antiendotoxin factor of Limulida based on GOR method with TALF functional area position as mould: RX1 NPT X2 KRLK X3 KYKGK X3 WCP as the first group, X4 INPT X2 KR X1 X4 X3 KYKGKFW as the second group, INPT X2 KRLKW X4 YKGR X3 X3 CP as the third group, PT X2 KR X1 KX3 KYKGKFWCP as the forth group, K X2 NPTVKR X1 K X3 RYKGKF as the fifth group, NPX5 VKR X1 K X3 RYKGKF as the sixth group, wherein six groups are synthesized into the peptide through solid phased peptide synthetic method by self-synthesizing and manual synthesizing, which produces the peptide with sterilizing and/or neutralizing LPS activity.

Description

technical field [0001] The invention relates to a limulus anti-endotoxin factor mimetic peptide molecule capable of killing bacteria and treating endotoxemia, its synthesis method and application. Background technique [0002] Gram-negative (G-) bacillary sepsis and shock are one of the main causes of death in clinical patients, especially G bacilli with severe endotoxin (Lipopolysaccharide, LPS) - Bacillus infection has a mortality rate of 50-80% [Crit. Care Med. 2001, 29(7): 1303-1310]. For the treatment of endotoxemia, due to the lack of specific therapeutic drugs, there are no effective measures at present, and it is limited to symptomatic treatment and antibacterial drugs, which leads to a high mortality rate of infectious diseases, so the pathogenesis of it is studied And finding effective treatment measures has always been the focus of clinical medicine. [0003] In recent years, with the in-depth research on G-bacteria infection, the role of LPS on the outer membra...

AI Technical Summary

Problems solved by technology

Although recombinant limulus anti-endotoxin factors (rLALF and rTALF) have been obtained through genetic engineering [J. However, the genetic engineering cycle is long and costly; although rLALF also has good LPS neutralizing and anti-G-bacteria activities, as seen in animal experiments, rLALF is not suitable for human treatment due to its potential antigenicity and toxic side effects[J .Biol.Chem, 1996, 271(8): 28120-28127]

Images